A Non-randomized, Open Label, Multi-center Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Patients With Metastatic and/or Unresectable GIST Resistant or Refractory to Prior Systemic Treatments Including Imatinib and Sunitinib.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2016
At a glance
- Drugs Ganetespib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Biomarker; Therapeutic Use
- Sponsors Synta Pharmaceuticals
- 03 Mar 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 20 Mar 2012 Planned End Date changed from 1 Nov 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 20 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported byClinicalTrials.gov.